CoChat

Study to determine the durability of glycaemic control with early treatment with a vildagliptin–metformin combination regimen vs. standard‐of‐care metformin monotherapy—the VERIFY trial: a randomized double‐blind trial

Open access
Del Prato, S., Foley, J. E., Kothny, W., Kozlovski, P., Stumvoll, M., Paldánius, P. M., Matthews, D. R. · 2014 · Diabetic Medicine
Cited by 39

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Aims: Durability of good glycaemic control (HbA 1c) is of importance as it can be the foundation for delaying diabetic complications. It has been hypothesized that early initiation of treatment with the combination of oral anti‐diabetes agents with complementary mechanisms of action can increase the durability of glycaemic control compared with metformin monotherapy followed by a stepwise addition of oral agents. Dipeptidyl peptidase‐4 inhibitors are good candidates for early use as they are efficacious in combination with metformin, show weight neutrality and a low risk of hypoglycaemia. We aimed to test the hypothesis that early combined treatment of metformin and vildagliptin slows β‐cell deterioration as measured by HbA 1c. Methods: Approximately 2000 people with Type 2 diabetes mellitus who were drug‐naive or who were treated with metformin for less than 1 month, and who have HbA 1c of 48–58 mmol/mol (6.5–7.5%), will be randomized in a 1:1 ratio in VERIFY, a 5‐year multinational, double‐blind, parallel‐group study designed to compare early initiation of a vildagliptin–metformin combination with standard‐of‐care initiation of metformin monotherapy, followed by the stepwise addition of vildagliptin when glycaemia deteriorates. Further deterioration will be treated with insulin. The primary analysis for treatment failure will be from a Cox proportional hazard regression model and the durability of glycaemic control will be evaluated by assessing treatment failure rate and the rate of loss in glycaemic control over time as co‐primary endpoints. Summary: VERIFY is the first study to investigate the long‐term clinical benefits of early combination treatment vs. the standard‐of‐care metformin monotherapy with a second agent added by threshold criteria.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dme.12508

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 39

Metadata

Authors
Del Prato, S., Foley, J. E., Kothny, W., Kozlovski, P., Stumvoll, M., Paldánius, P. M., & Matthews, D. R.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2014-07-17
Volume
31
Issue
10
Pages
1178-1184
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W2090447931
Cited by
39
References
6
FWCI
2.87
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Study to determine the durability of glycaemic control with early treatment with a vildagliptin–metformin combination regimen vs. standard‐of‐care metformin monotherapy—the VERIFY trial: a randomized double‐blind trial. https://app.cochat.ai/papers/10.1111/dme.12508
The paper
Del Prato, S., Foley, J. E., Kothny, W., Kozlovski, P., Stumvoll, M., Paldánius, P. M., & Matthews, D. R. (2014). Study to determine the durability of glycaemic control with early treatment with a vildagliptin–metformin combination regimen vs. standard‐of‐care metformin monotherapy—the VERIFY trial: a randomized double‐blind trial. Diabetic Medicine. https://doi.org/10.1111/dme.12508

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.